Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes
Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date
Federal Funding Cuts Would ‘Decimate’ Medical Research, Expert Warns
Rise in Prevalence of Obesity in Youth, Adults With T1DM Seen From 2008 to...
GLP-1 receptor agonist prescriptions increased significantly during study period across all categories of BMI, in dose-response manner
ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide
Greater Wealth Linked to Lower Mortality, With Stronger Link in U.S.
United States had a wider gap in survival between the top and bottom wealth quartiles compared with Europe
Judge Blocks Cuts to $11 Billion in Public Health Funding
ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes
ACC: Microplastic Exposure Tied to Chronic Disease Prevalence
Significant associations seen for high blood pressure, diabetes, and stroke
FDA Removes Top Expert on Vaping and Tobacco
FDA Approves Cabozantinib for Previously Treated Advanced Neuroendocrine Tumors
Patients treated with cabozantinib survived significantly longer with no worsening of their disease compared with patients who received placebo
